ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡ ÀÇÇÑ ³úÀüÀÌ È¯ÀÚÀÇ ¿¹ÈÄÀÎÀÚ
Prognostic Factors in Patients with Vrain Metastases from Non-Small Cell Lung Carcinoma
´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1991³â 9±Ç 2È£ p.197 ~ p.204
È«¼º¾ð(Hong Seong-Eon) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
Abstract
ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ ³úÀüÀÌ È¯ÀÚ¿¡¼ ¹æ»ç¼± Ä¡·áÈÄ ¿¹ÈÄÀÎÀÚ¸¦ ºÐ¼®Çϱâ À§ÇÏ¿© °æÈñ´ëÇÐ ºÎ¼Óº´¿ø Ä¡·á¹Ù»ç¼±°ú¿¡¼ Ä¡·á¹ÞÀº 53¿¹ÀÇ ¹æ»ç¼±Ä¡·á °á°ú¸¦ ºÐ¼®ÇÏ¿´´Ù. Àüü 53¿¹Áß ³²ÀÚ°¡ 37¸í ¿©ÀÚ°¡ 16¿¹ÀÌ°í ¿¬·ÉºÐÆ÷´Â 39¼¼ºÎÅÍ 85¼¼°¡Áö·Î Æò±Õ 59¼¼¿´´Ù. Á¶Á÷ÇÐÀû ¼Ò°ßÀº ¼±¾ÏÀÌ 27¿¹(50.9%)·Î °¡Àå ¸¹¾ÒÀ¸¸ç ÆíÆò¼¼Æ÷¾Ï(21¿¹), ´ë¼¼Æ÷¾Ï(5¿¹)¼øÀ̾ú´Ù. ¸ðµç ȯÀÚ¿¡¼ ½ºÅ×·ÎÀ̵åÅõ¿©¿Í ÇÔ²² Àü³úÁ¶»ç¸¦ ½ÃÇàÇÏ¿´´Ù. Àüü ÇÑÀÚÀÇ Áß°£»ýÁ¸ ±â°£Àº 5°³¿ùÀ̾ú°í, ³ªÀÌ, ¼ºº°, Á¶Á÷ÇüÅÂ, Ãʱ⠼öÇà»óÅ´ ¿¡ÈÄ¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê¾Ò´Ù. °¡Àå Áß¿äÇÑ ¿¹ÈÄÀÎÀÚ´Â ¹æ»ç¼±Ä¡·áÈÄ ¹ÝÀÀ¿©ºÎ¿Í ³úÀÌÀÇ ºÎÀ§ÀÇ ´Ù¹ß¼º ÀüÀÌ À¯¹«¿´´Ù. µû¶ó¼ ³úÀüÀÌ ´Üµ¶¼Ò°ßÀ» °¡Áø ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚ¿¡¼ ÀûÁ¤ÇÑ ¹æ»ç¼± Ä¡·á¼±·®À¸·Î Àû±ØÀûÀÎ Ä¡·á·Î½á »ýÁ¸±â°£À» ¿¬Àå½ÃÅ°°í quality if life¸¦ Çâ»ó½Ãų ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëÇÑ´Ù.
A retrospective study of 53 patients suffering from non-small cell carcinoma of lung with brain metastases is presented. They were treated in the Department of Therapeutic Radiology of Kyung Hee University Hospital from 1983 to 1990. There were 37 male and 16 female patients. The age range was 39 to 85 years (median=59). The most common histologic cell type of tumor was adenocarcinoma (50.9%), followed by squamous cell carcinoma and large cell carcinoma. All patients were treated with whole-brain photon irradiation(WBI) using lateral opposing fields.
The overall median survival time was 5 months. Age, sex, histologic type, and initial performance status were not prognostically important. The most important prognostic factors were the response to radiotherapy and the presence of brain metastases alone. Lncreasing the dose of radiotherapy to the main bulk of tumor may improve the symptom-free survival or overall survival in patients who present with brain metastases as the sole site of extrathoracic disease.
Å°¿öµå
Non-small cell lung cancer, Brain metastases, Radiotherapy
KMID :
0362919910090020197
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The overall median survival time was 5 months. Age, sex, histologic type, and initial performance status were not prognostically important. The most important prognostic factors were the response to radiotherapy and the presence of brain metastases.